Generic name: pertuzumab
2015 sales: $1.50 billion
2022 sales: $4.73 billion
Current indication: HER2-positive breast cancer
When Roche's Perjeta first launched in 2012, the jury was out as to whether the med would grow quickly enough to compensate for the expected decline in its $7-billon-a-year stablemate Herceptin once biosimilar competition gathered pace.
Four years later, those doubts have been largely laid to rest. Perjeta is one of the fastest-growing new products in Roche's portfolio, thanks to approvals for use in early-stage HER2-positive breast cancer that expand its initial use in more advanced disease. In fact, by 2022 Perjeta is predicted to add $3.2 billion to its annual sales, more than offsetting an expected $2.8 billion decline for Herceptin.
Giving it a big boost was its 2013 FDA nod as the first cancer drug approved for use before surgery, opening up a huge new group of eligible patients. The drug is used as a dual regimen alongside Herceptin or docetaxel chemotherapy to reduce the volume of breast tumors. The drug also set a precedent by becoming the first cancer drug approved by the FDA on the back of tumor shrinkage rather than survival data.